Announcements Trials
Browse Landscape

Status

Completed 23Terminated 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Pinealoma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Liver Neoplasms 1Head and Neck Neoplasms 1Glioma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Brain Stem Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 6Sunitinib 5Bevacizumab 4Sorafenib 3Radiotherapy 3Radiosurgery 3Nivolumab 3Magnetic Resonance Spectroscopy 3Interleukin-2 3Cyclophosphamide 3Axitinib 3tivozanib 2fludarabine phosphate 2durvalumab 2avelumab 2atezolizumab 2Peripheral Blood Stem Cell Transplantation 2Optical Imaging 2Nephrectomy 2Gene Expression Profiling 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2tremelimumab 1temsirolimus 1siltuximab 1sargramostim 1pazopanib 1pamiparib 1milademetan 1lenvatinib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Renal Cell × temsirolimus × Clear all
NCT01781442 2013-05-01

A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

Pfizer

Withdrawn
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡